Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance

Abstract Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly enhanced survival rates among patients with advanced non-small cell lung cancer (NSCLC) exhibiting EGFR mutations. However, acquired resistance diminishes their therapeutic efficacy over time. Recent inves...

Full description

Saved in:
Bibliographic Details
Main Authors: Linjuan Wang, Yue Qiu, Xiang Huang, Shimei Zhang, Min Zhao, Qiufang Chen
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Lipids in Health and Disease
Subjects:
Online Access:https://doi.org/10.1186/s12944-025-02559-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly enhanced survival rates among patients with advanced non-small cell lung cancer (NSCLC) exhibiting EGFR mutations. However, acquired resistance diminishes their therapeutic efficacy over time. Recent investigations have linked intracellular cholesterol with the emergence and advancement of various cancers. Elevated cholesterol levels could correlate with resistance to EGFR-TKIs in NSCLC. This review examines the association between cholesterol and EGFR-TKI resistance in NSCLC, with the objective of identifying more effective treatments and surmounting resistance.
ISSN:1476-511X